Actinium Pharmaceuticals, Inc. ATNM
of targeted radiotherapies to address significant unmet medical needs in oncology. We are focused on employing a biology-driven approach
to develop differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies.
Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing
toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.
Last close
1.52
2026-10-23
Market cap
$47.8M
2026-06-30 share count
52-week range
0.74 - 1.72
Valuation FY2025 figures against the last close
P/S531.0x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.09
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.0K | — | $81.0K | $1.0M | $1.1M | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $900.0K | — | — | — | — | — |
| Gross profit | — | — | — | — | $244.0K | — | — | — | — | — |
| R&D | $21.1M | $30.0M | $38.7M | $23.1M | $18.0M | $16.1M | $16.6M | $17.1M | $17.7M | $17.8M |
| SG&A | $15.2M | $12.1M | $13.3M | $12.0M | $8.1M | $6.3M | $5.5M | $6.7M | $9.2M | $9.0M |
| Total operating expenses | $36.3M | $42.1M | $52.0M | $35.1M | $26.1M | $22.4M | $22.1M | $23.8M | $26.9M | $26.8M |
| Operating income | -$36.2M | -$42.1M | -$51.9M | -$34.1M | -$25.0M | -$22.4M | -$22.1M | -$23.8M | -$26.9M | -$26.8M |
| Interest expense | — | — | $3.1M | $1.1M | $190.0K | $178.0K | $172.0K | $173.4K | $5.4K | $5.0K |
| Net income | -$33.9M | -$38.2M | -$48.8M | -$33.0M | -$24.8M | -$22.2M | -$21.9M | -$23.7M | -$26.6M | -$24.3M |
| EPS, basic | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | — | — | — | — | — |
| EPS, diluted | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 | -4.40 | -0.22 | -0.40 | -0.50 |
| Shares, diluted (wtd. avg.) | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.0M | $72.9M | $77.0M | $109.6M | $78.2M | $64.0M | $9.7M | $14.1M | $17.8M | $20.5M |
| Total current assets | $49.4M | $74.5M | $78.3M | $110.9M | $79.7M | $64.9M | $10.1M | $14.3M | $17.8M | $22.4M |
| Property, plant and equipment | $295.0K | $364.0K | $550.0K | $604.0K | $340.0K | $312.0K | $113.0K | $118.8K | $57.4K | $88.5K |
| Total assets | $51.8M | $76.9M | $81.4M | $114.2M | $80.4M | $66.4M | $11.7M | $14.9M | $18.3M | $22.5M |
| Accounts payable | $7.2M | $7.6M | $8.0M | — | — | $4.3M | $4.6M | $5.8M | $4.7M | $4.2M |
| Total current liabilities | $8.0M | $8.1M | $8.5M | $10.6M | $6.8M | $4.8M | $5.3M | $6.1M | $4.7M | $4.5M |
| Total liabilities | $43.9M | $44.1M | $45.1M | $47.7M | $6.8M | $5.1M | $6.0M | $6.1M | $4.7M | $4.5M |
| Retained earnings | -$409.7M | -$375.8M | -$337.6M | -$288.8M | -$255.7M | -$231.0M | -$208.8M | -$186.9M | -$163.2M | -$136.6M |
| Total equity | $7.8M | $32.8M | $36.4M | $66.5M | $73.5M | $61.3M | $5.6M | $8.8M | $13.7M | $18.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.6M | -$33.1M | -$47.3M | $8.6M | -$20.9M | -$21.6M | -$21.5M | -$20.6M | -$21.6M | -$20.8M |
| Depreciation and amortisation | $173.0K | $197.0K | $207.0K | $152.0K | $105.0K | $54.0K | $54.0K | $50.7K | $55.9K | $77.5K |
| Stock-based compensation | $9.2M | $5.3M | $3.8M | $2.8M | $1.7M | $1.3M | $1.3M | $1.8M | $3.5M | $4.3M |
| Capital expenditure | $104.0K | $11.0K | $153.0K | $366.0K | $133.0K | $253.0K | $64.0K | $96.1K | $24.7K | $60.0K |
| Investing cash flow | -$104.0K | -$11.0K | -$153.0K | -$366.0K | -$133.0K | -$253.0K | -$64.0K | -$96.1K | -$24.7K | -$109.8K |
| Financing cash flow | -$217.0K | $29.3M | $14.9M | $23.1M | $35.2M | $76.2M | $17.1M | $17.0M | $18.8M | $15.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036504.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $1.1M | $1.0M | $81.0K | — | $90.0K |
| Gross profit | — | — | — | — | — | $244.0K | — | — | — | — |
| Net income | -$24.3M | -$26.6M | -$23.7M | -$21.9M | -$22.2M | -$24.8M | -$33.0M | -$48.8M | -$38.2M | -$33.9M |
Recent filings and events
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Delisting notice Item 3.01
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Annual report filed Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |